^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    uliledlimab (TJD5)

    i
    Other names: TJD5, TJ004309, CD73 Antibody TJD5, TJ4309
    Company:
    I-Mab, PT Kalbe Farma, Tracon Pharma
    Drug class:
    CD73 inhibitor
    Related drugs:
    7ms
    A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors (clinicaltrials.gov)
    P2, N=25, Completed, I-Mab Biopharma US Limited | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • ER negative • PGR negative
    |
    Tecentriq (atezolizumab) • uliledlimab (TJD5)
    over1year
    A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, I-Mab Biopharma US Limited | Recruiting --> Active, not recruiting | N=60 --> 25 | Trial completion date: Jan 2025 --> Jun 2023 | Trial primary completion date: Oct 2024 --> Jun 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • ER negative • PGR negative
    |
    Tecentriq (atezolizumab) • uliledlimab (TJD5)
    over2years
    A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors (clinicaltrials.gov)
    P2, N=60, Recruiting, I-Mab Biopharma US Limited | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • ER negative • PGR negative
    |
    Tecentriq (atezolizumab) • uliledlimab (TJD5)
    almost3years
    A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, I-Mab Biopharma US Limited
    Clinical • New P2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • ER negative • PGR negative
    |
    Tecentriq (atezolizumab) • uliledlimab (TJD5)
    3years
    [VIRTUAL] Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer. (ASCO 2021)
    One patient failed nivolumab and the other received no prior PD-(L)1 inhibitor treatment . Uliledlimab is safe and well tolerated up to 20 mg/kg Q3W and 15 mg/kg QW . Full saturation of circulating and cell-bound CD73 was achieved at doses ≥ 10 mg/kg . Uliledlimab exhibited evidence of clinical activity in both PD-(L)1 treatment naïve and refractory cancer patients with high archival tumor expression of CD73 .
    Clinical • PK/PD data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression • CD73 expression
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • uliledlimab (TJD5)